Molecular Pathology of Rare Histologic Variants and Treatment-Resistant Lineages of Prostate Cancer

Most prostate cancers are classified as conventional acinar adenocarcinoma. However, a clinically significant subset consists of rare histologic variants and treatment-resistant lineages that exhibit distinct biological behaviors, molecular alterations, and therapeutic vulnerabilities. In our recent review published in Urologic Oncology, we provide an integrated overview of these entities and discuss their emerging molecular characteristics and clinical implications.

Rare epithelial subtypes—including intraductal carcinoma of the prostate (IDC-P), ductal adenocarcinoma, neuroendocrine prostate cancer (NEPC), double-negative prostate cancer (DNPC), basal cell carcinoma/adenoid cystic carcinoma, squamous cell carcinoma, and sarcomatoid carcinoma—often diverge substantially from conventional acinar adenocarcinoma in morphology, androgen receptor (AR) dependence, genomic instability, and response to therapy.

Among these, IDC-P has emerged as a particularly important pathological and prognostic entity. It is strongly associated with genomic instability, including frequent alterations in TP53, RB1, PTEN, and BRCA2. Spatial transcriptomic analyses further demonstrate that IDC-P forms a transcriptionally distinct intraductal niche characterized by hypoxia-related signaling and relative exclusion of immune and stromal components, suggesting a microenvironment that may promote tumor progression and therapeutic resistance.

Ductal adenocarcinoma, although uncommon, demonstrates aggressive clinical behavior and is enriched for DNA damage repair alterations, including homologous recombination repair and mismatch repair defects. These molecular features may have implications for precision treatment strategies in selected patients.

Treatment-resistant lineages, particularly treatment-related NEPC and DNPC, represent a major clinical challenge in advanced disease. These tumors are characterized by AR independence, frequent TP53 and RB1 loss, lineage plasticity, and activation of alternative transcriptional programs. Although several potential therapeutic targets have been identified, effective standard treatments remain limited.

Overall, rare and treatment-resistant prostate cancer subtypes underscore the biological heterogeneity of advanced disease and highlight the importance of integrating pathology, genomics, and emerging spatial technologies to refine diagnosis and inform future therapeutic strategies.

Written by: Ryuta Watanabe, MD, PhD, Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan; Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA

Read the Abstract

Login